Skip to Content
Biotechnology

A New Gene “Silencing” Drug Could Help Slow Huntington’s Disease

December 11, 2017

A human trial shows that synthetic strands of DNA meant to "silence" a problematic gene can slow down the production of a protein that leads to irreversible damage in the brain.

Huntington’s disease is caused by a mutation in the HTT gene that causes the body to create a rogue version of a protein called huntingtin; this altered protein damages parts of the brain. The new drug, called Ionis-HTTRx, is a small piece of synthetic DNA that blocks the production of that protein by silencing the HTT gene. The drug has to be injected into the fluid around the spine using a large needle.

Now the company behind the drug, Ionis Pharmaceuticals, reports that a phase 1 trial of 46 patients has shown that the drug successfully lowers the level of the toxic protein in the nervous system. And the results have caught the eye of Big Pharma: Roche has announced that it’s licensing the drug from Ionis for $45 million and will take on its development going forward.

Sarah Tabrizi, a professor of clinical neurology at University College London who ran the clinical trial, said in a statement that the results are of “ground-breaking importance for Huntington’s disease patients and families.” Now Roche will carry out further trials to investigate whether the reduced protein levels have a meaningful impact on the progression of the disease itself.

This isn’t the first time that so-called gene silencing drugs have been shown to be successful (see “How a Boy’s Lazarus-like Revival Points to a New Generation of Drugs” and “Gene-Silencing Drugs Finally Show Promise”). But it is the first drug to target the underlying cause of Huntington’s.

According to the Guardian, some researchers hope that the same technique could be modified and applied to other incurable brain diseases, like Alzheimer’s and Parkinson’s.

Deep Dive

Biotechnology

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.